FULCRUM THERAPEUTICS INC. - COMMON STOCK

Fulcrum Therapeutics Announces Publication of Results from Phase 2b Clinical Trial of Losmapimod in Facioscapulohumeral muscular dystrophy (ReDUX4) in The Lancet Neurology

08 май 2024 08:00:00 Источник Nasdaq GlobeNewswire

Fulcrum Therapeutics to Host First Quarter 2024 Financial Results Conference Call and Webcast on Monday, May 13, 2024, at 8:00 a.m. ET

06 май 2024 08:00:00 Источник Nasdaq GlobeNewswire

Fulcrum Therapeutics to Participate at the Cantor Virtual Muscular Dystrophy Symposium

28 мар 2024 16:05:00 Источник Nasdaq GlobeNewswire

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

22 мар 2024 16:30:00 Источник Nasdaq GlobeNewswire

Fulcrum Therapeutics Appoints Patrick Horn M.D., Ph.D., as Chief Medical Officer

18 мар 2024 07:00:00 Источник Nasdaq GlobeNewswire

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

08 мар 2024 16:30:00 Источник Nasdaq GlobeNewswire

Fulcrum Therapeutics to Participate at the Leerink Partners Global Biopharma Conference

05 мар 2024 08:00:00 Источник Nasdaq GlobeNewswire

Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Fourth Quarter and Full Year 2023

27 фев 2024 07:00:00 Источник Nasdaq GlobeNewswire

Fulcrum Therapeutics to Host Fourth Quarter and Full Year 2023 Financial Results Conference Call and Webcast on Tuesday, February 27, 2024, at 8:00 a.m. ET

20 фев 2024 16:01:00 Источник Nasdaq GlobeNewswire

Fulcrum Therapeutics to Participate at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

06 фев 2024 08:00:01 Источник Nasdaq GlobeNewswire

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

07 дек 2023 16:30:00 Источник Nasdaq GlobeNewswire

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

10 ноя 2023 16:30:00 Источник Nasdaq GlobeNewswire

Fulcrum Therapeutics to Participate at Upcoming November Investor Conferences

09 ноя 2023 08:00:00 Источник Nasdaq GlobeNewswire

Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Third Quarter 2023

07 ноя 2023 07:00:00 Источник Nasdaq GlobeNewswire

Fulcrum Therapeutics to Host Third Quarter 2023 Financial Results Conference Call and Webcast on Tuesday, November 7, 2023, at 8:00 a.m. ET

31 окт 2023 08:50:33 Источник Nasdaq GlobeNewswire

Fulcrum Therapeutics to Participate at the Cantor Fitzgerald Global Healthcare Conference

22 сен 2023 08:00:00 Источник Nasdaq GlobeNewswire

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

15 сен 2023 16:30:00 Источник Nasdaq GlobeNewswire

Fulcrum Announces Completion of Enrollment in the Phase 3 REACH Clinical Trial of Losmapimod in Facioscapulohumeral Muscular Dystrophy (FSHD)

07 сен 2023 08:00:00 Источник Nasdaq GlobeNewswire

FDA Lifts Clinical Hold on Fulcrum Therapeutics’ FTX-6058 for Sickle Cell Disease

22 авг 2023 07:00:00 Источник Nasdaq GlobeNewswire

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

11 авг 2023 16:53:28 Источник Nasdaq GlobeNewswire